Search

Dazostinag

Dazostinag is under investigation in clinical trial NCT04420884 (A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Sunvozertinib

[L53488] EGFR is a transmembrane protein with cytoplasmic kinase activity commonly expressed by non-small cell lung carcinomas (NSCLCs).

Orforglipron

Orforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. … [L56122,L56123] It was the first new molecular entity approved under the Commissioner’s National Priority Voucher (CNPV) pilot program, achieving a regulatory decision just 50 days after filing.

Baxdrostat

It targets aldosterone excess, a primary underlying driver of treatment resistance and organ damage in cardiovascular diseases [A275512, A275515]. … On May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189].

Calcimycin

Primarily used as a biochemical tool for studying divalent cations in biological systems, Calcimycin also exhibits antibiotic activity against gram-positive bacteria and fungi.

Azadirachtin

Azadirachtin is under investigation in clinical trial NCT06617026 (Short-term Outcome of Medical vs. Surgical Management of Chronic Anal Fissure).

Oveporexton

[L64069] Oveporexton has been recommended for scheduling as a controlled substance, and its final controlled-substance schedule and commercial availability are pending a determination by the Drug Enforcement

Dexfadrostat

Dexfadrostat is under investigation in clinical trial NCT04007406 (DP13 - a Phase II Study in Patients With Primary Aldosteronism).

Milsaperidone

Milsaperidone is an atypical antipsychotic agent that rapidly interconverts to iloperidone in vivo. Atypical antipsychotic agents work by blocking the D2 dopamine and serotonin receptor signalling pathways. Similarly, milsaperidone acts ...

AS-602868